NICHIBAN (4218) FY2027 Q1 Earnings Report

Quick View

Executive Summary

FY2027 Q1 saw an increase in revenue but a decrease in profit, with the key issue being that revenue growth has not translated into profit growth. Revenue was ¥12.26B (+2.9% YoY), Operating Income was ¥0.62B (-4.7%), Ordinary Income was ¥0.67B (-1.2%), and Net Income was ¥0.39B (+0.0%). The primary driver of revenue growth was the expansion of the industrial products field within the Tape Business; however, deteriorating profitability in the Medical Business and higher company-wide expenses weighed on Operating Income.

Factors Behind Performance Changes

【Revenue】Revenue increased 2.9% YoY to ¥12.26B. Both the Tape Business, at ¥6.28B (+4.3%), and the Medical Business, at ¥6.03B (+1.4%), recorded revenue growth. Within the Tape Business, the industrial products field increased 9.2% from ¥3.30B to ¥3.61B, serving as the main growth driver. In contrast, the medical materials field decreased 9.7% from ¥1.41B to ¥1.27B, while the overseas global field weakened in both businesses, declining 1.8% in the Medical Business and 24.2% in the Tape Business.

【Profit and Loss】Operating Income decreased 4.7% YoY to ¥0.62B. Segment profit in the Medical Business declined 9.9% YoY to ¥1.40B, while its profit margin fell by approximately 300bp from 26.2% to 23.2%. In contrast, the Tape Business recorded a substantial 65.1% increase in segment profit to ¥0.41B, with its profit margin improving by approximately 241bp from 4.1% to 6.5%. However, company-wide expenses increased 3.1% YoY to ¥1.15B, preventing the improvements at the segment level from being sufficiently reflected in consolidated profit. Ordinary Income was ¥0.67B (-1.2%), and Net Income was ¥0.39B (+0.0%), both essentially flat. An extraordinary loss of ¥0.04B, equivalent to 9.4% of Net Income, was a temporary downward factor. In conclusion, the Company achieved revenue growth but experienced a decline in profit.

Segment Analysis

The Tape Business recorded revenue of ¥6.28B (+4.3% YoY) and segment profit of ¥0.41B (+65.1%), resulting in both revenue and profit growth, with its profit margin improving from 4.1% to 6.5%. The primary factor was 9.2% revenue growth in the industrial products field. The Medical Business recorded revenue growth of 1.4% to ¥6.03B, but segment profit declined 9.9% to ¥1.40B, and its profit margin fell from 26.2% to 23.2%. The 9.7% decline in the medical materials field contributed to the deterioration in profitability. Combined segment profit was ¥1.81B, but after deducting ¥1.15B in unallocated company-wide expenses (+3.1% YoY), consolidated Operating Income remained at ¥0.62B. The pace of increase in company-wide expenses is restraining profit improvement.

Key Financial Indicators

【Profitability】The Operating Income margin was 5.1%, down approximately 41bp from approximately 5.5% in the same period of the previous year, while the Net Income margin was 3.2%, down approximately 9bp from approximately 3.3%. The gross profit margin was 30.6%, and the SG&A expense ratio was 25.6%; the increase in SG&A expenses exceeding revenue growth pressured profit margins.【Cash Flow Quality】The conversion rate from pretax income to Net Income was 62.3%, and the effective tax rate was approximately 37.6%. The extraordinary loss of ¥0.04B was equivalent to 9.4% of Net Income and was a temporary downward factor.【Investment Efficiency】Annualized ROE was approximately 3.6%, and the Equity Ratio was 67.1%. ROE was approximately 3.6% on an annualized basis, compared with the disclosed figure of 0.9% based on the simple quarterly figure.【Financial Soundness】Cash and deposits were ¥13.21B, while interest-bearing debt, consisting of long-term borrowings, was ¥1.00B. Current assets of ¥37.69B exceeded current liabilities of ¥14.71B by a substantial margin, indicating a strong ability to meet short-term obligations. The Equity Ratio of 67.1% improved from 65.9% in the same period of the previous year.

Cash Flow Analysis

Although no cash flow statement has been disclosed, financial trends can be inferred from changes in the balance sheet. Cash and deposits were ¥13.21B, down from ¥13.73B in the same period of the previous year. While accounts receivable decreased to ¥7.84B from ¥9.02B, inventories increased slightly to ¥5.61B from ¥5.46B, indicating greater cash tied up in inventory. Accounts payable decreased to ¥3.92B, and electronically recorded obligations decreased to ¥4.89B compared with the same period of the previous year; the reduction in trade payables also affected the cash balance. Net assets were ¥43.95B, slightly down from ¥44.33B in the same period of the previous year. Against the accumulation of profit, changes in working capital resulting from higher inventories and lower trade payables may have weighed on the cash balance.

Quality of Earnings

Current-period Operating Income of ¥0.62B was generated by deducting ¥1.15B in company-wide expenses from operating segment profit—¥1.40B in the Medical Business and ¥0.41B in the Tape Business, for a total of ¥1.81B—indicating that the earnings source is recurring and based on the underlying strength of the business segments. Non-operating income and expenses resulted in net income of ¥0.05B, including ¥0.02B in dividend income, but represented only 0.4% of revenue and did not substitute for core operating earnings. The extraordinary loss of ¥0.04B, including a ¥0.001B loss on disposal of fixed assets, was equivalent to 9.4% of Net Income and should be distinguished as a temporary downward factor. Comprehensive Income was ¥0.43B, exceeding Net Income of ¥0.39B. The primary factor was a ¥0.09B increase in valuation difference on securities, partially offset by a ¥0.03B decrease in adjustments related to retirement benefits. The difference between Net Income and Comprehensive Income was primarily attributable to the non-recurring valuation of securities and does not distort the underlying earning power of the core business.

Earnings Forecast and Guidance

The full-year plan calls for Revenue of ¥52.00B (+3.0% YoY), Operating Income of ¥3.60B (+58.5%), and Ordinary Income of ¥3.70B (+51.5%), with no revision to the earnings forecast. Q1 progress rates were 23.6% for Revenue, 17.3% for Operating Income, 18.1% for Ordinary Income, and 17.1% for Net Income, all below the 25% implied by even quarterly progress. In particular, the Operating Income plan assumes a substantial 58.5% YoY rebound. To recover from the decline in Q1, improvements in Medical Business profitability, continued revenue growth in the industrial products field, and control of company-wide expenses will be necessary.

Shareholder Returns

The full-year dividend forecast remains ¥40.00 per share, with no revision. Based on forecast full-year EPS of ¥113.06, the forecast Payout Ratio is 35.4%, remaining at a conservative level. The financial structure of ¥13.21B in cash and deposits and ¥1.00B in interest-bearing debt supports the Company’s dividend-paying capacity. However, Q1 progress toward the full-year Net Income plan of ¥2.30B was only 17.1%, meaning the stability of dividend funding depends on the achievement of the full-year profit plan.

Risk Factors

1. Declining profitability in the core business: Although the Medical Business recorded revenue of ¥6.03B, segment profit decreased 9.9% YoY to ¥1.40B, and its profit margin declined by approximately 300bp. Given the Company’s high dependence on this business, delays in restoring profitability could have a significant impact on consolidated profit.

2. Weakening overseas demand: The overseas global field declined in both businesses, falling 1.8% in the Medical Business and 24.2% in the Tape Business. A delayed recovery in overseas markets could constrain industrial product exports and other growth drivers.

3. Increase in company-wide expenses: Unallocated company-wide expenses increased 3.1% YoY to ¥1.15B, preventing the substantial increase in profit at the business segment level, including +65.1% in the Tape Business, from being sufficiently reflected in consolidated Operating Income, which declined 4.7%. Optimizing the cost structure will be a key focus going forward.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Return

The Company’s profitability is below the industry median, and its Net Income margin is positioned near the lower bound of the industry IQR.

Growth and Capital Efficiency

The Revenue growth rate is below the industry median but remains within the industry IQR range.

Source: Compiled by the Company

Key Takeaways from the Financial Results

1. Q1 Revenue increased 2.9%, while Operating Income decreased 4.7%, indicating from the earnings data that revenue growth has not been converted into profit growth. The decline of approximately 300bp in the Medical Business profit margin contrasts with the approximately 241bp improvement in the Tape Business profit margin.

2. The full-year plan assumes a substantial 58.5% YoY increase in Operating Income, but the Q1 progress rate was 17.3%, below the 25% implied by even quarterly progress. Performance from Q2 onward will therefore determine whether the plan can be achieved.

3. The Company has a conservative financial foundation, including an Equity Ratio of 67.1% and a high current ratio, providing sufficient financial capacity to implement measures aimed at improving profitability.

Theoretical Share Price (For Reference)

Sensitivity: ¥1,874–¥1,983 at ±1% for the cost of equity, and ¥1,919–¥1,933 at ±0.1 for ω.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end are used; there is a timing gap relative to the full-year forecast.
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmark is reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Nichiban’s FY2027 Q1 result was mixed: revenue expanded modestly, but operating-profit conversion weakened as selling and administrative costs outpaced sales. Revenue rose 2.9% YoY to ¥12.264bn. Gross profit increased 2.9% to ¥3.757bn, holding the gross margin virtually unchanged at 30.6%. Operating income declined 4.7% to ¥621m. The operating margin consequently contracted 40bp YoY to 5.1% from 5.5%. Ordinary income declined 1.2% to ¥668m, while profit attributable to owners was flat at ¥393m. The net margin eased by roughly 10bp to 3.2%. The flat net-profit outcome despite lower pretax profit was supported by income-tax expense falling 16.3% YoY to ¥237m. Medical remained the core business by segment-profit contribution, but its segment profit fell 9.9% YoY. Tape delivered the principal positive offset, with segment profit increasing 65.1% YoY. Domestic revenue increased 4.8%, led by industrial products and consumer-related fields, whereas overseas sales fell 12.2%. The full-year forecast calls for 3.0% revenue growth and a 58.5% increase in operating income, implying a substantial acceleration in margin recovery after Q1. Q1 revenue progress was 23.6% of the full-year plan, close to the standard 25% seasonal run rate. Operating-income progress was 17.3%, below the 25% reference point but not by more than the 10 percentage-point deviation threshold. The balance sheet remains conservatively funded, with a 256.2% current ratio, 67.1% equity ratio, and 51.75x interest coverage. The central near-term issues are restoring Medical profitability, translating Tape’s sales growth into sustained margins, and reducing the inventory intensity signaled by the inventory-day alerts.

Profitability Analysis

Annualized Q1 DuPont ROE was 3.6%, comprising a 3.2% net profit margin, 0.749x asset turnover, and 1.49x financial leverage. The low ROE is primarily a profitability issue rather than a balance-sheet leverage issue: financial leverage is restrained and the annualized asset-turnover ratio is moderate, while the net margin remains below the 5% level generally associated with strong profitability. The largest YoY operational movement was the 40bp contraction in operating margin to 5.1%. Gross margin was stable at 30.6%, indicating that the margin pressure arose below gross profit. SG&A increased 4.5% YoY to ¥3.135bn, exceeding 2.9% revenue growth; its sales ratio rose about 41bp to 25.6%. This negative operating leverage explains why operating income fell despite higher sales. The Medical segment generated ¥6.006bn of revenue, up 1.4%, and ¥1.402bn of segment profit, down 9.9%; its segment margin fell about 300bp to 23.3%. Tape generated ¥6.257bn of revenue, up 4.3%, and ¥411m of segment profit, up 65.1%; its segment margin rose about 242bp to 6.6%. Medical therefore remains the core business by segment-profit contribution, accounting for roughly 77% of aggregate segment profit, but its margin deterioration is the key drag on consolidated earnings. Tape’s improvement is encouraging, although its absolute margin remains well below Medical’s. The effective tax rate was 37.6%, producing a tax burden of 0.623, while the interest burden was a benign 1.016 and interest coverage was 51.75x. Ordinary income exceeded profit before tax by ¥37m because of extraordinary losses, equivalent to 5.5% of ordinary income and 9.4% of net income; this was not a major distortion of quarterly earnings.

Growth Assessment

Growth was concentrated in domestic operations. Domestic revenue increased from ¥10.542bn to ¥11.052bn, or 4.8% YoY, while overseas revenue decreased from ¥1.380bn to ¥1.211bn, or 12.2%. Within domestic sales, consumer-related revenue increased 5.9% to ¥6.175bn, industrial-products revenue rose 9.2% to ¥3.606bn, and medical-materials revenue declined 9.7% to ¥1.270bn. Industrial-products growth was the strongest identified revenue driver, while the reduction in medical-materials sales and lower overseas revenue constrain the breadth of the recovery. The unchanged gross margin suggests the company maintained pricing and production economics at the gross-profit level, but higher SG&A limited earnings conversion. Management maintained its full-year forecast of ¥52.0bn in revenue, ¥3.6bn in operating income, ¥3.7bn in ordinary income, and ¥2.3bn in net income. Q1 progress against those targets was 23.6% for revenue, 17.3% for operating income, 18.1% for ordinary income, and 17.1% for net income. The full-year guidance therefore requires operating-margin expansion from the Q1 5.1% level to 6.9% for the full year, alongside a much stronger profit conversion in subsequent quarters. This outlook is achievable only if the Medical segment stabilizes and Tape’s improved profitability persists while corporate-cost growth moderates.

Financial Health

Liquidity is strong. Current assets of ¥37.693bn were 2.56 times current liabilities of ¥14.713bn, and the quick ratio was 2.18 times. Working capital was ¥22.980bn, supported by ¥13.206bn of cash and deposits. Total equity was ¥43.948bn, representing a 67.1% equity ratio, while total liabilities were ¥21.538bn. Reported debt-to-equity was 0.49x and debt-to-capital was 2.2%, both consistent with a conservative solvency profile. Long-term loans were ¥1.0bn and interest coverage was a very strong 51.75x, limiting refinancing and interest-rate sensitivity. Current liabilities declined 14.5% YoY, improving the short-term funding profile. The net defined benefit liability was ¥1.918bn, and asset-retirement obligations were ¥765m. Asset-retirement obligations equal approximately 3.6% of total liabilities, an elevated but manageable environmental and site-restoration obligation for a manufacturing company. Property, plant and equipment represented 31.9% of total assets, consistent with a meaningful manufacturing asset base, while intangible assets were only 0.7% of assets, limiting acquisition-related intangible-asset risk.

Notable B/S Changes

Provision for bonuses: -¥668m (-53.5% YoY) to ¥580m - a substantial reduction in accrued bonus obligations contributed to lower short-term liabilities and should be monitored as a seasonal compensation-accrual movement. Net defined benefit liability: +¥63m (+3.4% YoY) to ¥1.918bn - pension obligations remain a notable non-current liability, although the increase was modest. Asset-retirement obligations: +¥3m (+0.4% YoY) to ¥765m - the balance was stable, but its approximately 3.6% share of total liabilities keeps environmental restoration exposure relevant.

Cash Flow Quality

Quarterly earnings were generated predominantly from operating activities, with operating income of ¥621m and net income of ¥393m. Gross profit rose in line with revenue, which supports the underlying earnings base, but the rise in SG&A above sales growth weakened conversion from gross profit to operating profit. The ¥37m extraordinary loss reduced pretax income but represented less than 10% of quarterly net income, limiting its effect on recurring earnings interpretation. Inventory increased 2.9% YoY to ¥5.612bn despite only 2.9% sales growth, which warrants close monitoring in a manufacturing business. The quality alerts identify inventory days of 103 days against a 90-day warning level and 60 days against the standard manufacturing efficiency threshold; both signals point to elevated inventory intensity. The likely implication is a greater risk of cash being tied up in finished goods and production inventory, as well as potential obsolescence or demand-forecast risk if sales momentum slows. Raw materials were ¥1.876bn and work in process was ¥2.111bn, while finished goods were ¥5.612bn. Management’s ability to normalize inventory relative to demand is therefore a key determinant of future cash conversion and working-capital efficiency.

Dividend Sustainability

The full-year dividend forecast is ¥40.00 per share, unchanged under the company’s disclosed forecast framework. Against forecast EPS of ¥113.06, the implied dividend payout ratio is approximately 35.4%. This is below the 60% sustainability benchmark and leaves a meaningful earnings retention buffer. The company’s strong liquidity, 67.1% equity ratio, low reported debt-to-capital ratio, and high interest coverage further support balance-sheet capacity for the planned dividend. Retained earnings stood at ¥33.006bn, providing substantial accumulated capital relative to the annual dividend commitment. Dividend sustainability will nevertheless depend on delivery of the significant second-half earnings recovery embedded in full-year guidance, particularly the planned 58.5% operating-income increase.

Risk Assessment

Business risks include Medical segment profitability risk: Medical segment profit declined 9.9% YoY to ¥1.402bn and segment margin fell about 300bp to 23.3%, despite revenue growth of 1.4%. As the core profit contributor, a prolonged decline would materially impair consolidated margin recovery., Overseas demand risk: overseas revenue fell 12.2% YoY to ¥1.211bn, creating uncertainty around the durability of international growth and geographic diversification., Manufacturing inventory risk: quality alerts show inventory days of 103 days and 60 days relative to warning and efficiency benchmarks. Elevated inventory can increase storage, obsolescence, markdown, and working-capital risks if demand weakens., Input-cost and pricing risk: the stable 30.6% gross margin is positive, but the company remains exposed to raw-material, energy, logistics, and labor-cost pressures typical of adhesive, medical-material, and industrial tape manufacturing..

Financial risks include Earnings-delivery risk: Q1 operating-income progress was 17.3% versus a standard 25% first-quarter run rate, requiring a marked improvement to achieve the ¥3.6bn full-year operating-income forecast., Environmental-obligation risk: asset-retirement obligations of ¥765m equal around 3.6% of total liabilities, indicating a meaningful exposure to future restoration and compliance costs., Tax-rate volatility risk: the Q1 effective tax rate was 37.6%, above a typical corporate-tax baseline, and tax expense was a meaningful driver of the conversion from pretax to net income..

Key concerns include CAPITAL_EFFICIENCY alert: ROIC of 4.9% is below the 5% warning threshold. This indicates that returns on the operating capital base remain modest; the cause is principally limited operating profitability, reflected in the 5.1% operating margin. With financial leverage low, the investment case depends on improving operating returns rather than increasing leverage., HIGH_INVENTORY_DAYS alert: 103 days exceeds the 90-day warning threshold. This is concerning because inventory can absorb capital and raise impairment or obsolescence risk; it is particularly relevant where demand differs by medical, consumer, and industrial end market., HIGH_INVENTORY_DAYS alert: 60 days is at the upper boundary of the stated manufacturing efficiency benchmark. Even this lower alert measure provides limited buffer against demand volatility, reinforcing the need to monitor inventory reduction and sales-through., Cost-control risk: SG&A grew 4.5% YoY against 2.9% revenue growth, lowering operating margin by 40bp. A continuation would challenge the substantial margin expansion assumed in full-year guidance..

Investment Implications

Key takeaways include Revenue growth remained positive at 2.9% YoY, supported by domestic consumer and industrial demand., Tape showed a meaningful earnings recovery, with segment profit up 65.1% YoY and margin improving to 6.6%., Medical remains the core business but needs margin restoration after its segment profit fell 9.9% YoY., The capital structure is robust, with a 256.2% current ratio, 67.1% equity ratio, 2.2% reported debt-to-capital, and 51.75x interest coverage., The full-year outlook embeds a material post-Q1 recovery in operating profitability..

Metrics to watch include Medical segment revenue and segment margin, Tape segment margin sustainability, SG&A growth relative to revenue growth, Overseas revenue trend, Inventory days, finished-goods balances, and inventory-to-sales progression, Progress toward the ¥3.6bn full-year operating-income forecast, ROIC improvement above the 5% threshold.

Regarding relative positioning, Nichiban combines a financially conservative balance sheet and resilient gross margin with currently modest capital efficiency. Relative positioning is therefore determined less by leverage capacity and more by whether its core Medical business can recover margins, whether Tape’s improved profitability can endure, and whether inventory intensity can be reduced.